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Abstract 
Introduction: Oral antibiotics are frequently prescribed for outpatient pulmonary 
exacerbations (PEx) in children with cystic fibrosis (CF). This study aimed to 
characterize oral antibiotic use for PEx and treatment outcomes at two large U.S. CF 
centers. 
Methods:Retrospective, descriptive study of oral antibiotic prescribing practices among 
children with CF ages 6- 17 years over one year. The care setting for antibiotic 
initiation(clinic or phone encounter) was determined and outcomes were compared. 
Results: 763 oral antibiotic courses were prescribed to 312 patients ages 6-17 years (77% 
of 403 eligible patients) with a median of 2 courses per year (range 1-10). Fifty-eight 
percent of prescriptions were provided over the phone. Penicillin was the most commonly 
prescribed antibiotic class (36% of prescriptions) but differences in antibiotic class 
prescriptions were noted between the two centers. Hospitalizations occurred within 3 
months following 19% of oral antibiotic courses. FEV1 recovered to within 90% of prior 
baseline within 6 months in 87% of encounters; the mean (SD) % recovery was 99.6% 
(12.1%) of baseline. Outcomes did not differ between phone and clinic prescriptions.  
Conclusions:Phone prescriptions, commonly excluded in studies of PEx, made up more 
than half of all oral antibiotic courses. Heterogeneity in prescribing patterns was observed 
between the two centers. Most patients had improvement in FEV1 returning to near their 
 














prior baseline, but hospitalizations occurred in one-fifth following oral antibiotic 
treatment. Efforts to optimize PEx treatment must consider care that occurs over the 
phone; this is particularly important as the use of telemedicine increases. 
Introduction 
 Pulmonary exacerbations (PEx) are frequent causes of morbidity for patients with 
cystic fibrosis (CF) and are characterized by an increase in respiratory symptoms above 
baseline including increased cough, sputum production and decreased exercise tolerance. 
While people with CF diagnosed with a PEx may require hospitalization for intravenous 
antibiotics, more than 70% of PEx are treated with oral antibiotics, and in children and 
those with milder lung disease the likelihood of oral antibiotic treatment is even higher1,2. 
Oral antibiotics are frequently prescribed over the phone in pediatric centers, but the 
extent to which this is done has not been characterized. Despite the routine use of 
outpatient oral antibiotics, there are limited data describing the prescribing patterns of 
oral antibiotics (e.g. whether antibiotics are prescribed in clinic or over the phone, the 
type of antibiotics used, treatment duration) and subsequent treatment outcomes3-6. As the 
use of remote monitoring for CF patients including phone calls and telehealth visits 
increases due to the COVID-19 pandemic, a better understanding of phone-treated PEx is 
warranted. 
Guidelines for oral antibiotic treatment of PEx are lacking although individual CF 
centers have developed local clinical care guidelines in an attempt to standardize 
decreases in forced expiratory volume in 1 second (FEV1) measurements and outpatient 
PEx treatment7. However, treatment guidelines often do not consider remote monitoring 
 














for PEx and their treatment when objective measurements including FEV1 are lacking. 
The COVID-19 pandemic has resulted in a rapid shift in CF care with more remote 
monitoring including telehealth visits and phone calls. It is likely that this shift will 
remain in the short term and may result in more permanent changes in the way that we 
approach CF care. Studies of Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) modulators have demonstrated a reduction in hospitalizations related to 
exacerbations and a shift towards more outpatient treatment8-12. It is also possible that 
with improvements in exacerbation frequency/severity and overall lung health that there 
will be shift towards more remote treatment of PEx for pediatric patients.  
We aimed to evaluate the heterogeneity of oral antibiotic treatment between two 
large pediatric CF centers and to characterize oral antibiotic prescribing patterns for PEx 
in children at two large CF centers. Secondarily, we sought to evaluate if there is a 
difference in PExoutcomes between those in which oral antibiotics were prescribed in 
clinic vs. over the phone. We hypothesized that there would be differences in antibiotic 
prescribing patterns between the two centers given the absence of standardized treatment 
guidelines for outpatient PEx. Additionally, we hypothesized that antibiotic prescriptions 
over the phone would be frequent in our clinic populations and be associated with a lower 
risk of subsequent hospitalization and better lung function recovery. We based this on the 
assumption that patients receiving antibiotics over the phone were recognizing symptoms 
and being treated earlier than those being seen in clinic. 
  
 















Study Population and Design 
 Children between the ages of 6 and 17 years of age with a diagnosis of CF13, and 
at least one PEx treated with oral antibiotics during the study period at Children’s 
Hospital Colorado (Aurora, CO) and Riley Hospital for Children (Indianapolis, IN) were 
included. All antibiotics prescribed fromJuly 2016-June 2017 were reviewed. A PEx 
treated with oral antibiotics was defined as a prescription of an acute course of oral 
antibiotics for worsening respiratory symptoms and/or signs.. Chronic oral and inhaled 
antibiotics were excluded. For each antibiotic prescription, the antibiotic prescribed and 
its duration and prescribing setting (clinic versus over the phone) were recorded. 
Demographic data, clinical characteristics and symptoms at the time of PEx, as well as 
outcomes of hospitalization during the subsequent 3 months and lung function 
measurements during the subsequent 6 months were obtained. All data were extracted 
from electronic medical records. 
Statistical Analysis 
 Descriptive statistics included the median and range and simple proportions, as 
applicable. The percent of antibiotics prescribed in each antibiotic class were compared 
between centers using a multinomial regression model with a random subject effect and a 
fixed center effect. Percent-predicted FEV1 was calculated using the Wang-
Hankinson14,15 reference equations. 
 Differences in outcomes between antibiotic prescriptions provided in clinic versus 
over the phone were measured by the proportion of patients hospitalized in the three 
months following an oral antibiotic prescription and recovery of baseline forced 
 














expiratory volume in 1 second (FEV1) within 6 months. The risk of hospitalizations in the 
three months following an oral antibiotic course was estimated between those with 
antibiotics prescribed in clinic versus over the phone using a logistic regression model 
with a random subject effect.  
 Baseline FEV1 (defined as highest FEV1 in the 6 months prior to the antibiotic 
course) were compared to the best FEV1 within 6 months following antibiotic treatment. 
For patients receiving antibiotics in clinic, the FEV1 at the time of antibiotic initiation 
was also obtained. To determine the percent of patients who returned to baseline in the 6 
months following the PEx, defined as 90% of baseline or higher16, logistic regression 
with a random subject effect was utilized. In addition, the percent of baseline FEV1 
recovered was determined by comparing the ratio of best FEV1 in the 6 months after 
treatment to the best FEV1 in the 6 months prior to treatment across groups using a linear 
mixed model. 
Based on observed differences in outcomes for the penicillin antibiotic class 
compared to other classes, a follow-up propensity score analysis was performed to reduce 
the impact of treatment-selection bias and estimate the effect of prescriptionsof different 
antibiotic classes on risk of hospitalization. Subjects were matched one-to-one using a 
Mahalanobis distance on the propensity score17 that was estimated using CF Center, care 
setting for treatment initiation (phone or clinic visit), highest FEV within 6 months prior 
and Stenotrophomonas culture result in a logistic regression using prescribed penicillin as 
the outcome. 
 














The Colorado Multiple Institutional Review Board and Indiana University 
Institutional Review Board approved this study. Consent was waived and HIPAA 
standards were maintained during the study. 
Results 
Demographics 
 Over a one-year period, 312/403 (77%) 6- to 17-year-old children with CF at 
Children's Hospital Colorado (CHCO) and Riley Hospital for Children (RHC) were 
prescribed at least one oral antibiotic course for an acute pulmonary exacerbation. A total 
of 763 oral antibiotic courses (437 CHCO, 326 RHC, E-Table 1) were prescribed with a 
median of two antibiotic courses per patient (range 1-10). Demographic data and clinical 
characteristics of the 312 subjects who received an antibiotic course are listed in Table 1. 
Baseline FEV1 was similar to the overall pediatric CF population at each center. 
Significant differences were noted in the culture results between the two centers, with 
RHC having a higher proportion of patients who were MRSA positive and a lower 
proportion positive for H. influenzae (p < 0.01 for both).  
Antibiotic Prescribing Patterns 
 Overall, 58% of antibiotics were prescribed over the phone, but differences 
existed between the two centers. Phone prescriptions were more common at CHCO 
compared to RHC (62% versus 52%, p<0.01, E-Table 2). There were 199 subjects (64% 
of cohort) between the two centers who received more than 1 antibiotic course; 
approximately half of these patients were prescribed antibiotics both in clinic and over 
the phone.  
 














 At both centers combined, the vast majority (90%) of antibiotic courses were 
prescribed for 14-21 days. At CHCO, 3.2% of antibiotic courses were prescribed for <14 
days compared to 16% at RHC. There was no difference in antibiotic prescription 
duration between phone and clinic antibiotic prescriptions when compared within site. 
The most common antibiotic prescribed differed between the two centers: amoxicillin-
clavulanic acid at CHCO (48%) and trimethoprim-sulfamethoxazole (38%) at RHC 
(Figure 1). There was no difference in the antibiotic class prescribed between clinic and 
phone encounters (E-Table 2) with the exception of infrequently prescribed antibiotics 
(<8% of total antibiotic courses). Additionally, there were no differences in age, gender, 
microbiology history or baseline FEV1 between phone and clinic prescriptions. Overall, 
antibiotic prescriptions were more common in the fall/winter months (October-March, 
430 prescriptions) compared to the spring/summer months (April-September, 333 
prescriptions, Figure 2). 
Reported signs and symptoms 
The most common symptom at the time of antibiotic prescription was an increase 
in cough (90%), followed by increased sputum (39%), fatigue (16%) and shortness of 
breath (11%). There were significant differences in reports of cough, increased sputum 
production, shortness of breath and fatigue between clinic and phone encounters (E-
Image 1, E-Table 3). Cough alone was recorded in 216 (28%) encounters. Multiple 
symptoms were reported in 478 (63%) encounters. The most common combination was 
increased cough, wet cough and change in sputum, which occurred in 108 (23%) of these 
encounters. There were 583 encounters that had symptom duration information; the 
median (IQR) duration was 5 (3-7) days. Clinic encounters had longer reported symptom 
 














duration compared to phone encounters (7 versus 4 days, p<0.01, E-Table 3). Chest 
exams were recorded in 306 (95%) of the clinic encounters. Abnormal breath sounds 
were noted in 32% of the clinic encounters. Of those with abnormal breath sounds, 
crackles (64%) were the most common finding followed by wheezing (20%) and rhonchi 
(13%). 
Hospitalizations  
 Hospitalization occurred within 3 months following 143 oral antibiotic 
prescriptions (18.7% of encounters) for a total of 110 discrete hospitalizations; 86 
hospitalizations occurred after 1 oral antibiotic course, 16 hospitalizations occurred after 
2 oral antibiotic courses and 7 and 1 hospitalizations occurred after 3 and 4 courses, 
respectively. There was no difference in the odds of hospitalization between clinic and 
phone encounters (p=0.82). Subjects who cultured positive for 
Stenotrophomonasmaltophilia any time over the one-year study period were more likely 
to be hospitalized (p-value=0.01, E-Table 4). There was no association between 
hospitalization and symptom duration in the subset of encounters (n=509) in which this 
information was documented. Those subjects who had higher baseline FEV1 % predicted 
or received treatment with penicillins (almost all amoxicillin-clavulanic acid) were less 
likely to be hospitalized (p < 0.01, E-Table 4). The association with reduced 
hospitalization and treatment with penicillin class antibiotics remained after performing a 
follow-up analysis using propensity score matching to better balance factors associated 
with penicillin prescriptions (E-Table 5). 
 














 There were 232 subjects who did not have a hospitalization within 3 months of 
any oral antibiotic treatment; the median (IQR) number of oral antibiotic courses for the 
non-hospitalized group was 2 (1-3). This was significantly lower than for the 80 subjects 
who did experience a hospitalization, with a median (IQR) of 3 (2-4) antibiotic courses 
during the one-year study period (p<0.01). 
Lung function recovery and changes in pulmonary function 
Median (IQR) baseline lung function (defined as highest FEV1 % predicted within 
the prior 6 months) was 96% (82, 107) predicted in the overall cohort with no significant 
difference between the two centers, nor between phone and clinic encounters. FEV1 
recovered to within 90% of baseline in 87% of encounters and >100% of baseline in 44% 
of encounters. The mean (sd) recovery of FEV1 was 99.6% (12.2%) and did not differ 
between clinic and phone encounters (E-Image 2, E-Table 6). Percent FEV1recovery was 
not different between those who were hospitalized within 3 months following an oral 
antibiotic course(98.8% [13.7]) and those who were not (99.8% [11.8], p=0.42). There 
was no association between antibiotic class prescribed and percent FEV1 recovery, but 
older age and higher baseline FEV1 were associated with worse recovery (E-Table 7). 
In the subset of encounters where antibiotics were prescribed in clinic (n=361), 
173 included FEV1 measurements at baseline (highest value within the past 6 months), at 
the clinic visit and within 6 months after antibiotics. The mean (sd) decrease in FEV1 
from the 6-month baseline to the start of antibiotics was -7.5% (11.8) predicted, with no 
significant difference between sites (E-Table 8), and the mean increase to the highest 
FEV1 within 6 months was 7% (9.6)predicted (Figure 3). Out of 173 clinic encounters 
 














with FEV1 values at the start of the antibiotic course, 92 (53%) had FEV1% >90% of 
baseline. Among the encounters at which antibiotics were prescribed but no symptoms 
recorded (11.5%), the mean (sd) drop in FEV1 from baseline was -9.8% (9.1) predicted.  
Discussion 
This study demonstrates that greater than 75% of school-aged children at two 
large pediatric CF centers experienced at least one PEx treated with oral antibiotics over 
one year. Previous registry-based studies have demonstrated that those with milder lung 
function and younger age are more likely to receive oral antibiotics versus IV antibiotics1. 
Therefore, it remains important to characterize exacerbations treated with oral antibiotics 
and their associated outcomes as this is a mainstay of treatment for pediatric patients.  
We hypothesized that the majority of antibiotic prescriptions would be over the 
phone and that those events would have improved outcomes based on earlier recognition 
and treatment. We found that 58% were indeed treated over the phone, and these PEx had 
a shorter duration of symptoms prior to treatment (4 vs 7 days). We did not detect 
difference in hospitalization rate or FEV1 recovery by treatment care setting in this 
retrospective, electronic health record-based study.  
Prescribing patterns between these two centers were heterogeneous; significant 
differences were noted in the antibiotic class prescribed, the proportion of phone versus 
clinic prescriptions and subsequent hospitalizations. Specifically, at CHCO, the most 
common antibiotic was amoxicillin-clavulanic acid, while at RHC it was trimethoprim-
sulfamethoxazole (TMP-SMX). This is likely due to the higher rate of MRSA within the 
cohort from RHC as well as differences in provider prescribing patterns. Of note, CHCO 
 














has an oral antibiotic guideline for treatment of outpatient PEx that recommends the use 
of amoxicillin-clavulanic acid as first line treatment for both MSSA and 
Haemophilusinfluenzae. Heterogeneity in IV antibiotic choice for CF pulmonary 
exacerbations has also been demonstrated for pediatric patients despite existing national 
guidelines for PEx treatment18. Antibiotic prescriptions over the phone were more 
common at CHCO, perhaps related to the large and mountainous geographic region it 
serves.  
Hospitalizations occurred following almost 20% of oral antibiotic courses in our 
cohorts. There are limited data on the risk of hospitalization following treatment with oral 
antibiotics. In a prospective study of IV antibiotics, half of adults and 75% of adolescents 
received oral antibiotics prior to hospitalization19. In a retrospective analysis of a cohort 
of pediatric and adult patients with CF performed over 1 year, 27% of PEx prescribed 
oral antibiotics were subsequently treated with IV antibiotics4, slightly higher than that 
observed in our cohort. This difference may be explained by the inclusion of both 
pediatric and adult patients and a lower average baseline FEV1 (~79%) in the prior 
study4. We also found that the risk of hospitalization following a PEx treated with 
antibiotics in the penicillin class was reduced compared to other antibiotics classes. It is 
unclear if this is related to the underlying CF pathogen or the antibiotic. Prospective 
studies are needed to better understand this finding.  
Despite the frequency of oral antibiotic use in the pediatric population and those 
with milder lung disease1, there are limited studies describing FEV1 outcomes following 
this treatment3-6. The average drop in lung function at the time of a PEx (-7.5%) was 
similar to the decreases observed in other studies3,5. The majority of patients in our cohort 
 














recovered to within 90% of their FEV1 baseline, suggesting that oral antibiotics are 
effective for most but there is likely a subgroup that do not respond well and need more 
aggressive therapy. Stanojevic and colleagues performed a large retrospective cohort 
study of adult and pediatric patients over a five-year period and evaluated the effect of 
oral antibiotic treated pulmonary exacerbations on short-term clinical outcomes5. They 
determined that lung function was lower in those who had an exacerbation treated with 
oral antibiotics in the previous year than those who did not, and that lung function decline 
over the five-year study period was greater in those that experienced more frequent 
exacerbations5. Almost 20% of subjects in the Toronto cohort treated with oral antibiotics 
did not return to within 90% of baseline at follow-up (within 3 months)5, higher than in 
our cohort. The timing of follow up lung function measurements and the inclusion of 
adults within the Toronto cohort may have contributed to this difference.  
In this study, recovery to baseline FEV1within 6 months was less likely in those 
who were older and had a higher baseline FEV1 which contrasts with prior studies 
showing older patients3,20 and those with higher baseline FEV1
3 were more likely to 
recover following exacerbation treatment. However, these differences may be related to 
the timing of FEV1 measurements and longer-term (within six month) versus shorter-term 
recovery. In children, higher baseline lung function is a risk factor for FEV1 decline
21,and 
it may be that inadequate recognition and/or insufficient treatment of PEx contribute to 
disease progression.  
The main strengths of this study are, for the first time, evaluation of PEx treated 
over the phone (which accounted for over half of all PEx), and inclusion of two large 
pediatric CF centers. Data collection occurred over a year to prevent any seasonality bias 
 














related to PEx outcomes and treatment. There are several limitations that must be noted. 
First, the study was retrospective and based on the electronic health record at the CF 
center, potentially leading to under-ascertainment of exacerbations, incomplete 
description of symptoms and exam findings and residual confounding by unmeasured 
characteristics. It is unlikely that there were a significant number of antibiotic courses 
prescribed at alternate locations based on the clinical practices at our centers. 
Additionally, we did not record whether patients were instructed to be seen in clinic 
based on their symptoms reported over the phone; if this occurred often, it would have 
biased the clinic group towards more severe PEx. We were also unable to assess 
adherence to oral antibiotic treatment and did not capture if patients were concomitantly 
treated with steroids or inhaled antibiotics. Furthermore, PEx symptoms treated without 
oral antibiotics (e.g., with increased frequency of airway clearance alone) were not 
assessed, limiting our ability to ascribe FEV1 improvements to the oral antibiotic 
prescriptions. Some individuals may have received more than one oral antibiotic course 
for a single PEx. Therefore, the changes observed may not be reflective of a single 
antibiotic course for a PEx but the repeated measures analysis did account for the fact 
that these were not independent observations.Additionally, we did not account for any 
antibiotics received shortly before or after the on-year study period. 
There is an urgent need to better understand remote monitoring of PEx, especially 
in the era of the COVID-19 pandemic and the rapid shifts in CF care to include more 
telemedicine visits and phone calls. This study highlights that there are several areas for 
future research including prospective evaluations of PEx treated remotely, identifying 
patients at risk for hospitalization or failure to recover to baseline lung function and 
 














determining the optimal timing of antibiotic initiation. Future studies of outpatient PEx 
management should include antibiotics prescribed over the phone, especially as the role 
of telemedicine expands22. 
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Figures 
Figure 1: Antibiotic prescriptions by class.Frequency of antibiotic class prescriptions 
prescribed at Children's Hospital Colorado (CHCO) and Riley Hospital for Children 
(RHC). The asterisks represent the antibiotic classes in which a significant difference was 
noted in the proportion of prescriptions between the two centers. 
 
 














Figure 2: Antibiotic prescriptions by month. a) The number of antibiotic prescriptions 
by month prescribed in clinic and over the phone at the two centers combined. b) The 


















Figure 3: Pulmonary function outcomes. Changes in FEV1 % predicted around 
antibiotic treatment are shown for a) the overall cohort (n = 670 encounters) and b) the 
subset of those prescribed antibiotics in clinic with FEV1% predicted available at all three 
time points (n = 173). ◊ indicates mean values; boxes represent 25th-75th percentiles; the 


























Number of subjects (% of total 
CF center population 6-17 years) 
180 (77%) 132 (78%) 312  
Female sex, n (%) 94 (52%) 67 (51%) 161 (52%) 0.80 
Age in years, median (IQR)a 11 (9, 14) 12 (9, 15) 12 (9, 14) 0.36 
Caucasian race 171 (95%) 125 (95%) 296 (95%) 0.90 
Hispanic ethnicity 25 (14%) 4 (3%) 29 (9%) <0.01 
Genotype:  
F508/F508 93 (52%) 81 (61%) 174 (56%)  
0.23 
 F508/Other 72 (40%) 43 (33%) 115 (37%) 
 Other/Other 15 (8%) 8 (6%) 23 (7%) 
Microbiologyb 
Pseudomonas aeruginosa 51 (28%) 39 (30%) 90 (29%) 0.82 
MSSA 131 (73%) 83 (63%) 214 (69%) 0.06 
MRSA 22 (12%) 41 (31%) 63 (20%) <0.01 
 














 H. influenza 60 (33%) 6 (5%) 66 (21%) <0.01 
Stenotrophomonas maltophilia 33 (18%) 20 (15%) 53 (17%) 0.46 
Baseline FEV1 % predicted,
c 
median (IQR) 
96 (85, 108) 
(n = 166) 
98 (86, 106) 
(n = 117) 
97 (85, 107) 0.94 
Number of oral antibiotic 
courses, median (range) 
2 (1, 9) 2 (1, 10) 2 (1, 10) 0.87 
a age of subject on July 1, 2016 (start of study) 
b from cultures within one year prior to first oral antibiotic treatment (not mutually 
exclusive) 
c highest FEV1 % predicted 6 months prior to first oral antibiotic treatment 
d p-values compare demographics between sites using either chi-square or Wilcoxon rank 
sum 
 
